University of California, Los Angeles About Us   |   Diversity and Inclusion  |   Contact Us   |   Campus Directory   |   Giving   |   Maps/Directions

Stephen Marder, M.D.

Contact Information:

Work Phone Number:

(800) 825-9989

Mailing Address:

UCLA Psychr & Biobehav Sci / VA Greater LA Healthcare Sys
BOX 951667, 11301 Wilshire Blvd. MIRECC Bldg 210, Rm 130
Los Angeles, CA 90073
UNITED STATES

Work Email Address:

marder@ucla.edu

Website:

Home Page.

Director, Section on Psychosis

Professor, Psychiatry and Biobehavioral Sciences

Professor in Residence, Semel Institute for Neuroscience and Human Behavior

Member, Adult Psychiatry

CTSI

Awards and Honors:

University of Southern California
Denver General Hospital, Denver, CO
National Institute of Mental Health

Detailed Biography:

Stephen R. Marder, M.D. received his A.B. from the University of Pennsylvania and his M.D. from the State University of New York at Buffalo. After an internship at Denver General Hospital he completed a residency at the University of Southern California. From 1975 to 1977 he was a Clinical Associate in the Biological Psychiatry Branch at the National Institute of Mental Health. In 1977 he joined the staff at the Brentwood VA Medical Center and the faculty at UCLA. Dr. Marder's research has focused on the drug treatment of schizophrenia and the pharmacology of antipsychotic drugs. He has authored or co-authored more than 200 journal articles and chapters based on research. The Schizophrenia Research Unit that he developed together with the late Theodore Van Putten has been an important site for training a number of psychiatrists who developed careers in research. He has been a Professor and Vice Chair of the Department of Psychiatry at UCLA since 1991. He is currently the Director of the VISN 22 Mental Illness Research, Education Clinical Center (MIRECC) for the Department of Veterans Affairs and the Director of the Section on Psychosis at the UCLA Neuropsychiatric Institute.

Publications:

Sherer Eric A, Sale Mark E, Pollock Bruce G, Belani Chandra P, Egorin Merrill J, Ivy Percy S, Lieberman Jeffrey A, Manuck Stephen B, Marder Stephen R, Muldoon Matthew F, Scher Howard I, Solit David B, Bies Robert R   Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building. Journal of pharmacokinetics and pharmacodynamics, 2012; 39(4): 393-414.
Keefe Richard S E, Vinogradov Sophia, Medalia Alice, Buckley Peter F, Caroff Stanley N, D'Souza Deepak C, Harvey Phillip D, Graham Karen A, Hamer Robert M, Marder Stephen M, Miller Del D, Olson Stephen J, Patel Jayendra K, Velligan Dawn, Walker Trina M, Haim Adam J, Stroup T Scott   Feasibility and pilot efficacy results from the multisite cognitive remediation in the schizophrenia trials network (CRSTN) randomized controlled trial. The Journal of clinical psychiatry, 2012; 73(7): 1016-22.
Velligan Dawn I, Rubin Maureen, Fredrick Megan M, Mintz Jim, Nuechterlein Keith H, Schooler Nina R, Jaeger Judith, Peters Nancy M, Buller Raimund, Marder Stephen R, Dube Sanjay   The cultural adaptability of intermediate measures of functional outcome in schizophrenia. Schizophrenia bulletin, 2012; 38(3): 630-41.
Javitt Daniel C, Buchanan Robert W, Keefe Richard S E, Kern Robert, McMahon Robert P, Green Michael F, Lieberman Jeffrey, Goff Donald C, Csernansky John G, McEvoy Joseph P, Jarskog Fred, Seidman Larry J, Gold James M, Kimhy David, Nolan Karen S, Barch Deanna S, Ball M Patricia, Robinson James, Marder Stephen R   Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophrenia research, 2012; 136(1-3): 25-31.
Glick Ira D, Correll Christoph U, Altamura A Carlo, Marder Stephen R, Csernansky John G, Weiden Peter J, Leucht Stefan, Davis John M   Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. The Journal of clinical psychiatry, 2011; 72(12): 1616-27.
Keefe Richard S E, Buchanan Robert W, Marder Stephen R, Schooler Nina R, Dugar Ashish, Zivkov Milana, Stewart Michelle   Clinical Trials of Potential Cognitive-Enhancing Drugs in Schizophrenia: What Have We Learned So Far? Schizophrenia bulletin, 2011; 72(12): .
Wessels Alette M, Bies Robert R, Pollock Bruce G, Schneider Lon S, Lieberman Jeffrey A, Stroup Scott, Li Claire H, Coley Kim, Kirshner Margaret M, Marder Stephen R   Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. Journal of clinical pharmacology, 2011; 51(11): 1587-91.
Buchanan Robert W, Keefe Richard S E, Umbricht Daniel, Green Michael F, Laughren Thomas, Marder Stephen R   The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophrenia bulletin, 2011; 37(6): 1209-17.
Marder Stephen R, Roth Bryan, Sullivan Patrick F, Scolnick Edward M, Nestler Eric J, Geyer Mark A, Welnberger Daniel R, Karayiorgou Maria, Guidotti Alessandro, Gingrich Jay, Akbarian Schahram, Buchanan Robert W, Lieberman Jeffrey A, Conn P Jeffrey, Haggarty Stephen J, Law Amanda J, Campbell Brian, Krystal John H, Moghaddam Bita, Sawa Akira, Saw Akira, Caron Marc G, George Susan R, Allen John A, Solis Michelle   Advancing drug discovery for schizophrenia. Annals of the New York Academy of Sciences, 2011; 1236(6): 30-43.
Keefe Richard S E, Vinogradov Sophia, Medalia Alice, Silverstein Steven M, Bell Morris D, Dickinson Dwight, Ventura Joseph, Marder Stephen R, Stroup T Scott   Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. Schizophrenia bulletin, 2011; 37(5): 1057-65.
Horan William P, Kern Robert S, Tripp Cory, Hellemann Gerhard, Wynn Jonathan K, Bell Morris, Marder Stephen R, Green Michael F   Efficacy and specificity of social cognitive skills training for outpatients with psychotic disorders. Journal of psychiatric research, 2011; 45(8): 1113-22.
Hurford Irene M, Marder Stephen R, Keefe Richard S E, Reise Steven P, Bilder Robert M   A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians. Schizophrenia bulletin, 2011; 37(3): 538-45.
Green Michael F, Schooler Nina R, Kern Robert S, Frese Fred J, Granberry Wendy, Harvey Philip D, Karson Craig N, Peters Nancy, Stewart Michelle, Seidman Larry J, Sonnenberg John, Stone William S, Walling David, Stover Ellen, Marder Stephen R   Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. The American journal of psychiatry, 2011; 168(4): 400-7.
Young Alexander S, Niv Noosha, Chinman Matthew, Dixon Lisa, Eisen Susan V, Fischer Ellen P, Smith Jeffrey, Valenstein Marcia, Marder Stephen R, Owen Richard R   Routine outcomes monitoring to support improving care for schizophrenia: report from the VA Mental Health QUERI. Community mental health journal, 2011; 47(2): 123-35.
Buchanan Robert W, Keefe Richard S E, Lieberman Jeffrey A, Barch Deanna M, Csernansky John G, Goff Donald C, Gold James M, Green Michael F, Jarskog L Fredrik, Javitt Daniel C, Kimhy David, Kraus Michael S, McEvoy Joseph P, Mesholam-Gately Raquelle I, Seidman Larry J, Ball M Patricia, McMahon Robert P, Kern Robert S, Robinson James, Marder Stephen R   A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biological psychiatry, 2011; 69(5): 442-9.
Marder Stephen R   Lessons from MATRICS. Schizophrenia bulletin, 2011; 37(2): 233-4.
Marder Stephen R, Daniel David G, Alphs Larry, Awad A George, Keefe Richard S E   Methodological issues in negative symptom trials. Schizophrenia bulletin, 2011; 37(2): 250-4.
Subotnik Kenneth L, Nuechterlein Keith H, Ventura Joseph, Gitlin Michael J, Marder Stephen, Mintz Jim, Hellemann Gerhard S, Thornton Leslie A, Singh Indira R   Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. The American journal of psychiatry, 2011; 168(3): 286-92.
Kern Robert S, Gold James M, Dickinson Dwight, Green Michael F, Nuechterlein Keith H, Baade Lyle E, Keefe Richard S E, Mesholam-Gately Raquelle I, Seidman Larry J, Lee Cathy, Sugar Catherine A, Marder Stephen R   The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophrenia research, 2011; 126(1-3): 124-31.
Kirkpatrick Brian, Strauss Gregory P, Nguyen Linh, Fischer Bernard A, Daniel David G, Cienfuegos Angel, Marder Stephen R   The brief negative symptom scale: psychometric properties. Schizophrenia bulletin, 2011; 37(2): 300-5.
Wessels Alette M, Pollock Bruce G, Anyama Norbert G, Schneider Lon S, Lieberman Jeffrey A, Marder Stephen R, Bies Robert R   Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial. Journal of clinical psychopharmacology, 2010; 30(6): 683-7.
Marder Stephen R, Sorsaburu Sebastian, Dunayevich Eduardo, Karagianis Jamie L, Dawe Ian C, Falk Deborah M, Dellva Mary Anne, Carlson Janice L, Cavazzoni Patrizia A, Baker Robert W   Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation. The Journal of clinical psychiatry, 2010; 71(4): 433-41.
Faerden Ann, Finset Arnstein, Friis Svein, Agartz Ingrid, Barrett Elizabeth Ann, Nesvåg Ragnar, Andreassen Ole A, Marder Stephen R, Melle Ingrid   Apathy in first episode psychosis patients: one year follow up. Schizophrenia research, 2010; 116(1): 20-6.
Jin Yuyan, Pollock Bruce G, Coley Kim, Miller Del, Marder Stephen R, Florian Jeff, Schneider Lon, Lieberman Jeffrey, Kirshner Margaret, Bies Robert R   Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. Journal of clinical pharmacology, 2010; 50(1): 73-80.
Kane John M, Correll Christoph U, Goff Donald C, Kirkpatrick Brian, Marder Stephen R, Vester-Blokland Estelle, Sun Wei, Carson William H, Pikalov Andrei, Assunção-Talbott Sheila   A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. The Journal of clinical psychiatry, 2009; 70(10): 1348-57.
Kern Robert S, Glynn Shirley M, Horan William P, Marder Stephen R   Psychosocial treatments to promote functional recovery in schizophrenia. Schizophrenia bulletin, 2009; 35(2): 347-61.
Janicak Philip G, Glick Ira D, Marder Stephen R, Crandall David T, McQuade Robert D, Marcus Ronald N, Eudicone James M, Assunção-Talbott Sheila   The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. The Journal of clinical psychiatry, 2009; 70(1): 25-35.
Feng Yan, Pollock Bruce G, Coley Kim, Marder Stephen, Miller Del, Kirshner Margaret, Aravagiri Manickam, Schneider Lon, Bies Robert R   Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. British journal of clinical pharmacology, 2008; 66(5): 629-39.
Webber Michael A, Marder Stephen R   Better pharmacotherapy for schizophrenia: what does the future hold? Current psychiatry reports, 2008; 10(4): 352-8.
Marder Stephen R   Treatment of agitation in patients with schizophrenia. The Journal of clinical psychiatry, 2008; 69(6): e17.
Kim Jin Hun, Kim Daeho, Marder Stephen R   Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry, 2008; 32(4): 984-8.
Krystal John H, Carter Cameron S, Geschwind Daniel, Manji Husseini K, March John S, Nestler Eric J, Zubieta Jon-Kar, Charney Dennis S, Goldman David, Gur Raquel E, Lieberman Jeffrey A, Roy-Byrne Peter, Rubinow David R, Anderson Stewart A, Barondes Samuel, Berman Karen F, Blair James, Braff David L, Brown E Sherwood, Calabrese Joseph R, Carlezon William A, Cook Edwin H, Davidson Richard J, Davis Michael, Desimone Robert, Drevets Wayne C, Duman Ronald S, Essock Susan M, Faraone Stephen V, Freedman Robert, Friston Karl J, Gelernter Joel, Geller Barbara, Gill Michael, Gould Elizabeth, Grace Anthony A, Grillon Christian, Gueorguieva Ralitza, Hariri Ahmad R, Innis Robert B, Jones Edward G, Kleinman Joel E, Koob George F, Krystal Andrew D, Leibenluft Ellen, Levinson Douglas F, Levitt Pat R, Lewis David A, Liberzon Israel, Lipska Barbara K, Marder Stephen R, Markou Athina, Mason Graeme F, McDougle Christopher J, McEwen Bruce S, McMahon Francis J, Meaney Michael J, Meltzer Herbert Y, Merikangas Kathleen R, Meyer-Lindenberg Andreas, Mirnics Károly, Monteggia Lisa M, Neumeister Alexander, O'Brien Charles P, Owen Michael J, Pine Daniel S, Rapoport Judith L, Rauch Scott L, Robbins Trevor W, Rosenbaum Jerrold F, Rosenberg David R, Ross Christopher A, Rush A John, Sackeim Harold A, Sanacora Gerard, Schatzberg Alan F, Shaham Yavin, Siever Larry J, Sunderland Trey, Tecott Laurence H, Thase Michael E, Todd Richard D, Weissman Myrna M, Yehuda Rachel, Yoshikawa Takeo, Young Elizabeth A, McCandless R   It is time to take a stand for medical research and against terrorism targeting medical scientists. Biological psychiatry, 2008; 63(8): 725-7.
Zhu Baojin, Ascher-Svanum Haya, Shi Lizheng, Faries Douglas, Montgomery William, Marder Stephen R   Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiatric services (Washington, D.C.), 2008; 59(3): 315-7.
Green Michael F, Nuechterlein Keith H, Kern Robert S, Baade Lyle E, Fenton Wayne S, Gold James M, Keefe Richard S E, Mesholam-Gately Raquelle, Seidman Larry J, Stover Ellen, Marder Stephen R   Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. The American journal of psychiatry, 2008; 165(2): 221-8.
Bigos Kristin L, Pollock Bruce G, Coley Kim C, Miller Del D, Marder Stephen R, Aravagiri Manickam, Kirshner Margaret A, Schneider Lon S, Bies Robert R   Sex, race, and smoking impact olanzapine exposure. Journal of clinical pharmacology, 2008; 48(2): 157-65.
Nuechterlein Keith H, Green Michael F, Kern Robert S, Baade Lyle E, Barch Deanna M, Cohen Jonathan D, Essock Susan, Fenton Wayne S, Frese Frederick J, Gold James M, Goldberg Terry, Heaton Robert K, Keefe Richard S E, Kraemer Helena, Mesholam-Gately Raquelle, Seidman Larry J, Stover Ellen, Weinberger Daniel R, Young Alexander S, Zalcman Steven, Marder Stephen R   The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. The American journal of psychiatry, 2008; 165(2): 203-13.
Kern Robert S, Nuechterlein Keith H, Green Michael F, Baade Lyle E, Fenton Wayne S, Gold James M, Keefe Richard S E, Mesholam-Gately Raquelle, Mintz Jim, Seidman Larry J, Stover Ellen, Marder Stephen R   The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. The American journal of psychiatry, 2008; 165(2): 214-20.
Faerden Ann, Nesvåg Ragnar, Marder Stephen R   Definitions of the term 'recovered' in schizophrenia and other disorders. Psychopathology, 2008; 41(5): 271-8.
Foerde Karin, Poldrack Russell A, Khan Barbara J, Sabb Fred W, Bookheimer Susan Y, Bilder Robert M, Guthrie Don, Granholm Eric, Nuechterlein Keith H, Marder Stephen R, Asarnow Robert F   Selective corticostriatal dysfunction in schizophrenia: examination of motor and cognitive skill learning. Neuropsychology, 2008; 22(1): 100-9.
Marder Stephen R, Kramer Michelle, Ford Lisa, Eerdekens Els, Lim Pilar, Eerdekens Mariëlle, Lowy Adam   Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biological psychiatry, 2007; 62(12): 1363-70.
Bratti Irene M, Kane John M, Marder Stephen R   Chronic restlessness with antipsychotics. The American journal of psychiatry, 2007; 164(11): 1648-54.
Moore Troy A, Buchanan Robert W, Buckley Peter F, Chiles John A, Conley Robert R, Crismon M Lynn, Essock Susan M, Finnerty Molly, Marder Stephen R, Miller Del D, McEvoy Joseph P, Robinson Delbert G, Schooler Nina R, Shon Steven P, Stroup T Scott, Miller Alexander L   The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. The Journal of clinical psychiatry, 2007; 68(11): 1751-62.
Sergi Mark J, Green Michael F, Widmark Clifford, Reist Christopher, Erhart Stephen, Braff David L, Kee Kimmy S, Marder Stephen R, Mintz Jim   Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. The American journal of psychiatry, 2007; 164(10): 1585-92.
Buchanan Robert W, Javitt Daniel C, Marder Stephen R, Schooler Nina R, Gold James M, McMahon Robert P, Heresco-Levy Uriel, Carpenter William T   The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. The American journal of psychiatry, 2007; 164(10): 1593-602.
Wynn Jonathan K, Green Michael F, Sprock Joyce, Light Gregory A, Widmark Clifford, Reist Christopher, Erhart Stephen, Marder Stephen R, Mintz Jim, Braff David L   Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophrenia research, 2007; 95(1-3): 134-42.
Stover Ellen L, Brady Linda, Marder Stephen R   New paradigms for treatment development. Schizophrenia bulletin, 2007; 33(5): 1093-9.
Pierre Joseph M, Peloian John H, Wirshing Donna A, Wirshing William C, Marder Stephen R   A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. The Journal of clinical psychiatry, 2007; 68(5): 705-10.
Marder Stephen R, West Britt, Lau Gina S, Pultz Joseph A, Pikalov Andrei, Marcus Ronald N, Gutierrez-Esteinou Rolando, Crandall David T   Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. The Journal of clinical psychiatry, 2007; 68(5): 662-8.
Shi Lizheng, Ascher-Svanum Haya, Zhu Baojin, Faries Douglas, Montgomery William, Marder Stephen R   Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatric services (Washington, D.C.), 2007; 58(4): 482-8.
Aravagiri Manickam, Marder Stephen R, Pollock Bruce   Determination of ziprasidone in human plasma by liquid chromatography-electrospray tandem mass spectrometry and its application to plasma level determination in schizophrenia patients. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2007; 847(2): 237-44.
Marder Stephen R   Lessons from each drug trial. The American journal of psychiatry, 2007; 164(3): 375-6.
Sergi Mark J, Rassovsky Yuri, Widmark Clifford, Reist Christopher, Erhart Stephen, Braff David L, Marder Stephen R, Green Michael F   Social cognition in schizophrenia: relationships with neurocognition and negative symptoms. Schizophrenia research, 2007; 90(1-3): 316-24.
Davis John M, Marder Stephen R, Tamminga Carol A   Switch or stay? The American journal of psychiatry, 2006; 163(12): 2032-3.
Marder Stephen R   Initiatives to promote the discovery of drugs to improve cognitive function in severe mental illness. The Journal of clinical psychiatry, 2006; 67(7): e03.
Marder Stephen R   A review of agitation in mental illness: treatment guidelines and current therapies. The Journal of clinical psychiatry, 2006; 67 Suppl 10(1): 13-21.
Charuvastra Anthony, Marder Stephen   Commentary on "TM and our models of informed consent" by Charles W. Lidz. Behavioral sciences & the law, 2006; 24(4): 547-52.
Marder Stephen R   Drug initiatives to improve cognitive function. The Journal of clinical psychiatry, 2006; 67 Suppl 9(1): 31-5; discussion 36-42.
Kirkpatrick Brian, Fenton Wayne S, Carpenter William T, Marder Stephen R   The NIMH-MATRICS consensus statement on negative symptoms. Schizophrenia bulletin, 2006; 32(2): 214-9.
Marder Stephen R   The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia. Dialogues in clinical neuroscience, 2006; 8(1): 109-13.
Erhart Stephen M, Marder Stephen R, Carpenter William T   Treatment of schizophrenia negative symptoms: future prospects. Schizophrenia bulletin, 2006; 32(2): 234-7.
Erhart Stephen M, Young Alexander S, Marder Stephen R, Mintz Jim   Clinical utility of magnetic resonance imaging radiographs for suspected organic syndromes in adult psychiatry. The Journal of clinical psychiatry, 2005; 66(8): 968-73.
Glick Ira D, Marder Stephen R   Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. The Journal of clinical psychiatry, 2005; 66(5): 638-41.
McGurk Susan R, Carter Cameron, Goldman Robert, Green Michael F, Marder Stephen R, Xie Haiyi, Schooler Nina R, Kane John M   The effects of clozapine and risperidone on spatial working memory in schizophrenia. The American journal of psychiatry, 2005; 162(5): 1013-6.
Albers Lawrence J, Ozdemir Vural, Marder Stephen R, Raggi Maria Augusta, Aravagiri Manickam, Endrenyi Laszlo, Reist Christopher   Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy. Journal of clinical psychopharmacology, 2005; 25(2): 170-4.
Andreasen Nancy C, Carpenter William T, Kane John M, Lasser Robert A, Marder Stephen R, Weinberger Daniel R   Remission in schizophrenia: proposed criteria and rationale for consensus. The American journal of psychiatry, 2005; 162(3): 441-9.
Quintana Javier, Wong Tiffany, Ortiz-Portillo Elena, Marder Stephen R, Mazziotta John C   Anterior cingulate dysfunction during choice anticipation in schizophrenia. Psychiatry research, 2004; 132(2): 117-30.
Mohr Penny E, Cheng C Michael, Claxton Karl, Conley Robert R, Feldman Jacob J, Hargreaves William A, Lehman Anthony F, Lenert Leslie A, Mahmoud Ramy, Marder Stephen R, Neumann Peter J   The heterogeneity of schizophrenia in disease states. Schizophrenia research, 2004; 71(1): 83-95.
Green Michael F, Nuechterlein Keith H, Gold James M, Barch Deanna M, Cohen Jonathan, Essock Susan, Fenton Wayne S, Frese Fred, Goldberg Terry E, Heaton Robert K, Keefe Richard S E, Kern Robert S, Kraemer Helena, Stover Ellen, Weinberger Daniel R, Zalcman Steven, Marder Stephen R   Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biological psychiatry, 2004; 56(5): 301-7.
Marder Stephen R, Essock Susan M, Miller Alexander L, Buchanan Robert W, Casey Daniel E, Davis John M, Kane John M, Lieberman Jeffrey A, Schooler Nina R, Covell Nancy, Stroup Scott, Weissman Ellen M, Wirshing Donna A, Hall Catherine S, Pogach Leonard, Pi-Sunyer Xavier, Bigger J Thomas, Friedman Alan, Kleinberg David, Yevich Steven J, Davis Bonnie, Shon Steven   Physical health monitoring of patients with schizophrenia. The American journal of psychiatry, 2004; 161(8): 1334-49.
Friedlander Arthur H, Marder Stephen R, Sung Eric C, Child John S   Panic disorder: psychopathology, medical management and dental implications. Journal of the American Dental Association (1939), 2004; 135(6): 771-8; quiz 796-7.
Miller Alexander L, Hall Catherine S, Buchanan Robert W, Buckley Peter F, Chiles John A, Conley Robert R, Crismon M Lynn, Ereshefsky Larry, Essock Susan M, Finnerty Molly, Marder Stephen R, Miller Del D, McEvoy Joseph P, Rush A John, Saeed Sy A, Schooler Nina R, Shon Steven P, Stroup Scott, Tarin-Godoy Bernardo   The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. The Journal of clinical psychiatry, 2004; 65(4): 500-8.
Bellack Alan S, Schooler Nina R, Marder Stephen R, Kane John M, Brown Clayton H, Yang Ye   Do clozapine and risperidone affect social competence and problem solving? The American journal of psychiatry, 2004; 161(2): 364-7.
Friedlander Arthur H, Friedlander Ida K, Marder Stephen R   Posttraumatic stress disorder: psychopathology, medical management, and dental implications. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2004; 97(1): 5-11.
Marder Stephen R, Fenton Wayne, Youens Kenneth   Schizophrenia, IX: Cognition in schizophrenia--the MATRICS initiative. The American journal of psychiatry, 2004; 161(1): 25.
Aravagiri Manickam, Marder Stephen R, Nuechterlein Keith H, Gitlin Michael J   Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Therapeutic drug monitoring, 2003; 25(6): 657-64.
Marder Stephen R, Glynn Shirley M, Wirshing William C, Wirshing Donna A, Ross Doreen, Widmark Clifford, Mintz Jim, Liberman Robert P, Blair Karen E   Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. The American journal of psychiatry, 2003; 160(8): 1405-12.
Potkin Steven G, Saha Anutosh R, Kujawa Mary J, Carson William H, Ali Mirza, Stock Elyse, Stringfellow Joseph, Ingenito Gary, Marder Stephen R   Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of general psychiatry, 2003; 60(7): 681-90.
Friedlander Arthur H, Marder Stephen R, Pisegna Joseph R, Yagiela John A   Alcohol abuse and dependence: psychopathology, medical management and dental implications. Journal of the American Dental Association (1939), 2003; 134(6): 731-40.
Marder Stephen R, McQuade Robert D, Stock Elyse, Kaplita Stephen, Marcus Ronald, Safferman Allan Z, Saha Anutosh, Ali Mirza, Iwamoto Taro   Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia research, 2003; 61(2-3): 123-36.
Quintana Javier, Wong Tiffany, Ortiz-Portillo Elena, Marder Stephen R, Mazziotta John C   Right lateral fusiform gyrus dysfunction during facial information processing in schizophrenia. Biological psychiatry, 2003; 53(12): 1099-112.
Marder Stephen R, Conley Robert, Ereshefsky Larry, Kane John M, Turner Martin S   Clinical guidelines: Dosing and switching strategies for long-acting risperidone. The Journal of clinical psychiatry, 2003; 64 Suppl 16(1): 41-6.
Marder Stephen R   Overview of partial compliance. The Journal of clinical psychiatry, 2003; 64 Suppl 16(1): 3-9.
Quintana Javier, Wong Tiffany, Ortiz-Portillo Elena, Kovalik Edward, Davidson Tom, Marder Stephen R, Mazziotta John C   Prefrontal-posterior parietal networks in schizophrenia: primary dysfunctions and secondary compensations. Biological psychiatry, 2003; 53(1): 12-24.
Tsuang John W, Eckman Thad, Marder Stephen, Tucker Doug   Can risperidone reduce cocaine use in substance abusing schizophrenic patients? Journal of clinical psychopharmacology, 2002; 22(6): 629-30.
Tsuang John, Marder Stephen R, Han Amanda, Hsieh Winnie   Olanzapine treatment for patients with schizophrenia and cocaine abuse. The Journal of clinical psychiatry, 2002; 63(12): 1180 -1.
Merlo Marco C G, Hofer Helene, Gekle Walter, Berger Gregor, Ventura Joseph, Panhuber Ingrid, Latour Gabriela, Marder Stephen R   Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. The Journal of clinical psychiatry, 2002; 63(10): 885-91.
Wirshing Donna A, Boyd Jennifer A, Meng Laura R, Ballon Jacob S, Marder Stephen R, Wirshing William C   The effects of novel antipsychotics on glucose and lipid levels. The Journal of clinical psychiatry, 2002; 63(10): 856-65.
Friedlander Arthur H, Friedlander Ida K, Marder Stephen R   Bipolar I disorder: psychopathology, medical management and dental implications. Journal of the American Dental Association (1939), 2002; 133(9): 1209-17.
Liberman Robert P, Glynn Shirley, Blair Karen E, Ross Doreen, Marder Stephen R   In vivo amplified skills training: promoting generalization of independent living skills for clients with schizophrenia. Psychiatry, 2002; 65(2): 137-55.
Wirshing Donna A, Pierre Joseph M, Marder Stephen R, Saunders C Scott, Wirshing William C   Sexual side effects of novel antipsychotic medications. Schizophrenia research, 2002; 56(1-2): 25-30.
Green Michael F, Marder Stephen R, Glynn Shirley M, McGurk Susan R, Wirshing William C, Wirshing Donna A, Liberman Robert P, Mintz Jim   The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biological psychiatry, 2002; 51(12): 972-8.
Umbricht Daniel S, Wirshing William C, Wirshing Donna A, McMeniman Marjorie, Schooler Nina R, Marder Stephen R, Kane John M   Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. The Journal of clinical psychiatry, 2002; 63(5): 420-4.
Glynn Shirley M, Marder Stephen R, Liberman Robert P, Blair Karen, Wirshing William C, Wirshing Donna A, Ross Doreen, Mintz Jim   Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia. The American journal of psychiatry, 2002; 159(5): 829-37.
Friedlander Arthur H, Marder Stephen R   The psychopathology, medical management and dental implications of schizophrenia. Journal of the American Dental Association (1939), 2002; 133(5): 603-10; quiz 624-5.
Kane John M, Davis John M, Schooler Nina, Marder Stephen, Casey Daniel, Brauzer Benjamin, Mintz Jim, Conley Robert   A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. The American journal of psychiatry, 2002; 159(4): 554-60.
Aravagiri Manickam, Marder Stephen R   Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. Psychopharmacology, 2002; 159(4): 424-31.
Marder Stephen R   Can clinical practice guide a research agenda? Schizophrenia bulletin, 2002; 28(1): 127-9.
Marder Stephen R, Essock Susan M, Miller Alexander L, Buchanan Robert W, Davis John M, Kane John M, Lieberman Jeffrey, Schooler Nina R   The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophrenia bulletin, 2002; 28(1): 5-16.
UCLA    |    Terms & Conditions    |    Disability Resources    |    UC Regents